BioCardia, Inc. (BCDA): Price and Financial Metrics


BioCardia, Inc. (BCDA): $2.42

0.07 (+2.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BCDA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BCDA Stock Summary

  • BCDA has a higher market value than merely 11.38% of US stocks; more precisely, its current market capitalization is $41,928,528.
  • With a price/sales ratio of 31.64, BIOCARDIA INC has a higher such ratio than 95.33% of stocks in our set.
  • With a year-over-year growth in debt of 957.14%, BIOCARDIA INC's debt growth rate surpasses 97.78% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to BIOCARDIA INC, a group of peers worth examining would be CRBU, CRDF, VERU, RXRX, and TGTX.
  • BCDA's SEC filings can be seen here. And to visit BIOCARDIA INC's official web site, go to www.biocardia.com.

BCDA Valuation Summary

  • In comparison to the median Healthcare stock, BCDA's price/sales ratio is 519.61% higher, now standing at 31.6.
  • BCDA's EV/EBIT ratio has moved up 38.1 over the prior 243 months.

Below are key valuation metrics over time for BCDA.

Stock Date P/S P/B P/E EV/EBIT
BCDA 2023-01-20 31.6 10.2 -3.4 -3.0
BCDA 2023-01-19 31.8 10.3 -3.4 -3.0
BCDA 2023-01-18 31.5 10.2 -3.4 -3.0
BCDA 2023-01-17 31.3 10.1 -3.4 -3.0
BCDA 2023-01-13 30.9 10.0 -3.3 -2.9
BCDA 2023-01-12 31.6 10.2 -3.4 -3.0

BCDA Growth Metrics

    Its year over year price growth rate is now at -64.46%.
  • Its 2 year price growth rate is now at -73.36%.
  • The 3 year revenue growth rate now stands at 60.28%.
Over the past 33 months, BCDA's revenue has gone up $615,000.

The table below shows BCDA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.325 -10.539 -12.34
2022-06-30 1.934 -11.176 -11.989
2022-03-31 1.029 -11.396 -12.979
2021-12-31 1.015 -10.366 -12.623
2021-09-30 0.982 -10.808 -12.151
2021-06-30 0.195 -11.769 -13.293

BCDA Price Target

For more insight on analysts targets of BCDA, see our BCDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.17 Average Broker Recommendation 1.62 (Moderate Buy)

BCDA Stock Price Chart Interactive Chart >

Price chart for BCDA

BCDA Price/Volume Stats

Current price $2.42 52-week high $2.85
Prev. close $2.35 52-week low $1.10
Day low $2.32 Volume 50,689
Day high $2.45 Avg. volume 38,094
50-day MA $1.99 Dividend yield N/A
200-day MA $1.78 Market Cap 48.51M

BioCardia, Inc. (BCDA) Company Bio


BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.


BCDA Latest News Stream


Event/Time News Detail
Loading, please wait...

BCDA Latest Social Stream


Loading social stream, please wait...

View Full BCDA Social Stream

Latest BCDA News From Around the Web

Below are the latest news stories about BIOCARDIA INC that investors may wish to consider to help them evaluate BCDA as an investment opportunity.

BioCardia Letter to Shareholders

SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders: Dear Shareholders,BioCardia is now advancing four novel cell therapies, with three focused on heart disease, a leading cause of death and reduced quality of life globally. The Phase III trial of our lead therapy - CardiAMP® autologous cell th

Yahoo | December 22, 2022

$1 Million Bet On BioCardia? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones settled higher on Tuesday after recording losses for four straight sessions. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. BioCardia The Trade: BioCardia, Inc. (NASDAQ: BCDA ) 10% owner Frost Gamma Investments Trust bought a total of 595,238 shares at an average price of $1.68. To acquire these shares, it cost around $1 million. What’s Happening: BioCardia announced a $3.6 million pri...

Benzinga | December 21, 2022

Insider Buying: The BioCardia, Inc. (NASDAQ:BCDA) Independent Director Just Bought 14% More Shares

Potential BioCardia, Inc. ( NASDAQ:BCDA ) shareholders may wish to note that the Independent Director, Simon Stertzer...

Yahoo | December 21, 2022

BioCardia sinks 9% on $3.6M private placement of common stock

BioCardia (BCDA) to raise $3.6M through a private placement of common stock The company has entered into a securities purchase and registration rights agreement with certain new…

Seeking Alpha | December 15, 2022

BioCardia Announces $3.6 Million Private Placement of Common Stock

SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration Rights Agreement (the “Purchase Agreement”) relating to a private placement with certain new

Wallstreet:Online | December 15, 2022

Read More 'BCDA' Stories Here

BCDA Price Returns

1-mo 32.97%
3-mo 22.22%
6-mo 66.90%
1-year 60.26%
3-year -51.11%
5-year -90.22%
YTD 15.79%
2022 7.73%
2021 -43.93%
2020 -5.98%
2019 -65.93%
2018 -48.94%

Continue Researching BCDA

Here are a few links from around the web to help you further your research on BioCardia Inc's stock as an investment opportunity:

BioCardia Inc (BCDA) Stock Price | Nasdaq
BioCardia Inc (BCDA) Stock Quote, History and News - Yahoo Finance
BioCardia Inc (BCDA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.649 seconds.